

# Gastrointestinal Therapeutics Market to Reach \$64.5 Billion, Globally, by 2032 | Bayer AG, AbbVie, Takeda Pharmaceutical

PORTLAND, IN, UNITED STATES, March 17, 2025 /EINPresswire.com/ -- According to the report, the global [gastrointestinal therapeutics industry](#) generated \$39.5 billion in 2022, and is anticipated to generate \$64.5 billion by 2032, witnessing a CAGR of 5.0% from 2023 to 2032. □

Gastrointestinal therapeutics is a specialized medical discipline dedicated to the diagnosis and management of disorders that affect the gastrointestinal tract. Within this medical field, the primary emphasis is on addressing conditions that impact various organs within the gastrointestinal system, including the stomach, small intestine, large intestine, and rectum. Gastrointestinal therapeutics encompass a broad spectrum of interventions, including the use of medications to alleviate symptoms, enhance the overall functioning of the gastrointestinal system, and improve the quality of life for individuals dealing with these ailments. □

Request Sample of the Report: <https://www.alliedmarketresearch.com/request-sample/3535>

Increase in prevalence of gastrointestinal diseases, rise in geriatric population, rise in number of product launches drive the growth of the global gastrointestinal therapeutics market. However, the stringent government regulations toward approval of biosimilars and patent expiry of drugs restrict market growth. Moreover, rise in research and development activities and growth opportunities in emerging markets such as rise in funding activities, demand for better healthcare facilities and surge in need for gastrointestinal therapeutics presents new opportunities in the coming years. □

## Recession Impact □

During a recession, individuals and governments might tighten their budgets, leading to reduced healthcare spending. This could affect patient ability to access and afford gastrointestinal medications and treatments, potentially leading to decreased demand for these therapeutics. In addition, economic uncertainty during a recession might cause individuals to delay or avoid non-essential medical visits, including routine check-ups for gastrointestinal issues. □

However, the rise in research and development activities for gastrointestinal therapeutics and increase in number of pipeline products for gastrointestinal diseases is experiencing a moderate positive impact from the global recession. □

Procure Complete Report at 20% Discount (320 Pages PDF with Insights, Charts, Tables, and

Figures)

<https://www.alliedmarketresearch.com/checkout-final/gastrointestinal-therapeutics-market>

The biologics segment to maintain its leadership status throughout the forecast period

Based on drug class, the biologics segment held the largest market share in 2022, accounting for around one third of the global gastrointestinal therapeutics market revenue and is estimated to maintain its leadership status throughout the forecast period. This segment is projected to manifest the highest CAGR of 6.9% from 2023 to 2032, owing to high adoption of biologics as they are highly targeted and effective treatments for complex gastrointestinal disorders.

The inflammatory bowel disease segment to maintain its leadership status throughout the forecast period

Based application, the inflammatory bowel disease segment held the largest market share in 2022, accounting for more than half of the global gastrointestinal therapeutics market and is estimated to maintain its leadership status throughout the forecast period. This segment is projected to manifest the highest CAGR of 5.5% from 2023 to 2032, owing to surge in cases of inflammatory bowel disease along with advancements in treatment options and surge in awareness among healthcare professionals and patients.

The drug stores and retail pharmacies segment to maintain its lead position during the forecast period

Based on distribution channel, the drug stores and retail pharmacies segment accounted for the largest share in 2022, contributing to nearly three-fifths of the global gastrointestinal therapeutics market revenue, and is projected to maintain its lead position during the forecast period. This is attributed to high accessibility and making it convenient for patients to access gastrointestinal therapeutics medications easily. However, the online providers segment is expected to witness the fastest CAGR of 5.6% from 2023 to 2032. This is attributed to surge in adoption of telemedicine and digital healthcare platforms. As technological advancements continue to facilitate remote consultations, prescription services, and medication deliveries, patients are drawn to the convenience, accessibility, and personalized nature of online healthcare solutions, driving the surge in demand for gastrointestinal therapies through online providers.

For Purchase Inquiry: <https://www.alliedmarketresearch.com/purchase-enquiry/3535>

North America to maintain its dominance by 2032

Based on region, North America held the largest market share in terms of revenue in 2022, accounting for more than two-fifths of the global gastrointestinal therapeutics market revenue and is likely to dominate the market during the forecast period. Easy availability of drugs for

treatment, well-developed healthcare infrastructure, and rise in prevalence of gastrointestinal diseases promoted the growth of the gastrointestinal therapeutics market in North America.□

However, the Asia-Pacific region is expected to witness the fastest CAGR of 6.4% from 2023 to 2032. High prevalence of geriatric population with increase in need of diagnostic procedures, surge in prevalence of gastrointestinal diseases, rise in research and development activities in fields such as pharmaceuticals, and life sciences and surge in healthcare expenditure in the Asia-Pacific region, is expected to drive the growth of the gastrointestinal therapeutics market.□

Leading Market Players:

AbbVie Inc.□

Astrazeneca plc□

Pfizer Inc.□

Bayer AG□

Bausch Health Companies Inc.□

Takeda Pharmaceutical Company Limited□

Cosmo Pharmaceuticals□

Organon Group of Companies□

Bristol-Myers Squibb Company□

Teva Pharmaceutical Industries Limited

About Allied Market Research:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Wilmington, Delaware. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

David Correa  
Allied Market Research  
+ 1800-792-5285

[email us here](#)

Visit us on social media:

[Facebook](#)

[X](#)

[LinkedIn](#)

[YouTube](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/794541446>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.